Colin John Meyer, Chief Research Officer at REATA PHARMACEUTICALS INC (RETA), sold 46,950 shares at $170.48 ($8.0M) on 2020-11-16, disclosed to the SEC on 2020-11-18.
Open-market sale of $8.0M RETA by Chief Research Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $170.48 | 12,174 | $2.1M | 26.0% |
| 2 | $170.48 | 12,174 | $2.1M | 26.0% |
| 3 | $171.38 | 3,824 | $655K | 8.2% |
| 4 | $171.38 | 3,824 | $655K | 8.2% |
| 5 | $172.61 | 2,207 | $381K | 4.8% |
| 6 | $172.61 | 2,207 |
| $381K |
| 4.8% |
| 7 | $173.75 | 100 | $17K | 0.2% |
| 8 | $174.98 | 200 | $35K | 0.4% |
| 9 | $175.00 | 100 | $18K | 0.2% |
| 10 | $164.44 | 2,450 | $403K | 5.1% |
| 11 | $165.25 | 1,815 | $300K | 3.8% |
| 12 | $165.25 | 1,815 | $300K | 3.8% |
| 13 | $166.14 | 1,930 | $321K | 4.0% |
| 14 | $166.14 | 1,930 | $321K | 4.0% |
| 15 | $170.59 | 200 | $34K | 0.4% |
| Total | $169.79 avg | 46,950 | $8.0M | 100% |
| Filing → |
| RETA | SELL | 2023-03-08 | $105K | — | Filing → |
| RETA | SELL | 2023-03-06 | $16.3M | — | Filing → |
| RETA | SELL | 2021-06-16 | $16.4M | — | Filing → |